Literature DB >> 8139646

Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia.

A Cometta, T Calandra, J Bille, M P Glauser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8139646     DOI： 10.1056/NEJM199404283301717

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  29 in total

Review 1.  Management of febrile neutropenia in low risk cancer patients.

Authors:  B A Oppenheim; H Anderson
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

2.  The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephone.

Authors:  Toshiro Mizuno; Noriyuki Katsumata; Hirofumi Mukai; Chikako Shimizu; Masashi Ando; Toru Watanabe
Journal:  Support Care Cancer       Date:  2006-08-29       Impact factor: 3.603

3.  In vitro antimicrobial activity of moxifloxacin against bacterial strains isolated from blood of neutropenic cancer patients.

Authors:  A Cometta; O Marchetti; T Calandra; J Bille; W V Kern; S Zinner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

4.  Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia.

Authors:  W V Kern; K Klose; A S Jellen-Ritter; M Oethinger; J Bohnert; P Kern; S Reuter; H von Baum; R Marre
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

5.  Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients: clonal analysis.

Authors:  M Oethinger; A S Jellen-Ritter; S Conrad; R Marre; W V Kern
Journal:  Infection       Date:  1998 Nov-Dec       Impact factor: 3.553

6.  Emergence and infectious complications of ciprofloxacin-resistant Escherichia coli in haematological cancer patients.

Authors:  M G van Kraaij; A W Dekker; E Peters; A Fluit; L F Verdonck; M Rozenberg-Arska
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-08       Impact factor: 3.267

7.  Characterization of bacterial infections in allogeneic hematopoietic stem cell transplant recipients who received prophylactic levofloxacin with either penicillin or doxycycline.

Authors:  Bridgette L Therriault; John W Wilson; Jason N Barreto; Lynn L Estes
Journal:  Mayo Clin Proc       Date:  2010-08       Impact factor: 7.616

8.  Murine model of chemotherapy-induced extraintestinal pathogenic Escherichia coli translocation.

Authors:  Sabrina I Green; Nadim J Ajami; Li Ma; Nina M Poole; Roger E Price; Joseph F Petrosino; Anthony W Maresso
Journal:  Infect Immun       Date:  2015-06-01       Impact factor: 3.441

Review 9.  The intestinal microbiota and susceptibility to infection in immunocompromised patients.

Authors:  Ying Taur; Eric G Pamer
Journal:  Curr Opin Infect Dis       Date:  2013-08       Impact factor: 4.915

Review 10.  Rethinking Antimicrobial Prophylaxis in the Transplant Patient in the World of Emerging Resistant Organisms-Where Are We Today?

Authors:  Lucy E Horton; Nina M Haste; Randy A Taplitz
Journal:  Curr Hematol Malig Rep       Date:  2018-02       Impact factor: 3.952
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.